Supernus Boosts Therapy Portfolio With Finalized Buyout of Adamas

Supernus Boosts Therapy Portfolio With Finalized Buyout of Adamas

312892

Supernus Boosts Therapy Portfolio With Finalized Buyout of Adamas

Supernus Pharmaceuticals’ portfolio of Parkinson’s disease therapies now includes Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride), with the company’s acquisition of Adamas Pharmaceuticals now complete. “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” Jack Khattar, president and CEO of Supernus Pharmaceuticals, said in a press release. The acquisition is expected to boost Supernus’ growth in 2022 and follows a $450 million agreement — $50 million of which is contingent…

You must be logged in to read/download the full post.